Immunocore Holdings plc Increase (Decrease) in Accounts Payable
Immunocore Holdings plc (IMCR) reported Increase (Decrease) in Accounts Payable of $1.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Immunocore Holdings plc increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$4.80M.
- Immunocore Holdings plc increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $5.97M, a 78.76% increase year-over-year.
- Immunocore Holdings plc increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.42M, a 75.90% decline year-over-year.
- Immunocore Holdings plc increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$287.00K.
- Immunocore Holdings plc increase (decrease) in accounts payable for fiscal 2025 was -$2.46M, a 133.77% decline from fiscal 2024.
- Immunocore Holdings plc increase (decrease) in accounts payable for fiscal 2024 was $7.27M, a 177.03% increase from fiscal 2023.
- Immunocore Holdings plc increase (decrease) in accounts payable for fiscal 2023 was $2.63M, a 46.57% decline from fiscal 2022.
- Immunocore Holdings plc increase (decrease) in accounts payable for fiscal 2022 was $4.91M, a 233.31% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.17M 10-Q · filed 2026-08-06 | $2.59M derived: sum of 3 quarters · filed 2026-08-06 | $2.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.97M 10-Q · filed 2026-05-06 | $7.39M derived: sum of 2 quarters · filed 2026-05-06 | $7.11M derived: sum of 3 quarters · filed 2026-05-06 | $176.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.13M derived: sum of 2 quarters · filed 2026-02-25 | -$5.80M derived: sum of 3 quarters · filed 2026-08-06 | -$2.46M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$7.22M derived: sum of 2 quarters · filed 2026-08-06 | -$3.87M 10-Q · filed 2025-11-06 | $2.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$6.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.59M 10-Q · filed 2026-08-06 | $2.30M derived: sum of 3 quarters · filed 2026-08-06 | $1.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.34M 10-Q · filed 2026-05-06 | $9.23M derived: sum of 2 quarters · filed 2026-05-06 | $8.45M derived: sum of 3 quarters · filed 2026-05-06 | $12.93M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.11M derived: sum of 2 quarters · filed 2026-02-25 | $9.59M derived: sum of 3 quarters · filed 2026-02-25 | $7.27M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$776.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.71M derived: sum of 2 quarters · filed 2025-11-06 | $1.39M 10-Q · filed 2025-11-06 | $5.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.16M 10-Q · filed 2025-08-07 | $5.92M derived: sum of 3 quarters · filed 2026-02-25 | $1.83M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$2.32M 10-Q · filed 2025-05-07 | $1.44M derived: sum of 2 quarters · filed 2026-02-25 | -$2.66M derived: sum of 3 quarters · filed 2026-02-25 | $3.32M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$337.00K derived: sum of 2 quarters · filed 2026-02-25 | $5.64M derived: sum of 3 quarters · filed 2026-02-25 | $2.63M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.89M derived: sum of 2 quarters · filed 2024-11-06 | -$1.13M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $5.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.96M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$3.02M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $4.91M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $1.47M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |